Clinical trials
Phase 2 Study clinical trials
Below are recruiting phase 2 study clinical trials, each written for real people, not researchers. We’re tracking 1,327 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06660420RecruitingPhase 1
PRAME-targeted NK cells for advanced melanoma
This trial tests a new type of cell therapy using your own immune cells (NK cells) modified to target a protein called PRAME found on melanoma cells. It is for people whose melanoma has not responded to or has returned after standard immunotherapies.
Houston, TexasAges 18 years+ - NCT07106892RecruitingPhase 2
Testing HLX43 for advanced colorectal cancer
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
BeijingAges 3 weeks–2 months - NCT07115485RecruitingPhase 2
Study of HLX43 for advanced stomach or junction cancer
This trial tests a new drug called HLX43 (an antibody-drug conjugate targeting PD-L1) for people with advanced stomach or gastroesophageal junction cancer that has progressed after at least one prior treatment. It aims to see if it can shrink tumors and help patients live longer.
BeijingAges 3 weeks–2 months - NCT07857733RecruitingPhase 3
Extended treatment study for complex regional pain syndrome
This study gives an extended course of neridronate infusions to people who completed the earlier AMBTX-01-301 trial, to see if longer treatment safely keeps easing their chronic pain and other symptoms of complex regional pain syndrome (a long-lasting pain condition, often after an injury).
Phoenix, ArizonaAges 18 years+ - NCT05746897RecruitingPhase 1
First-in-human test of an anti-PVRIG drug for advanced cancers
This early-phase study tests NM1F (an anti-PVRIG antibody) in people with advanced solid tumors to see if it’s safe and whether it may work. It also includes pembrolizumab (a PD-1 “checkpoint” medicine), aiming to boost the immune system against the cancer.
Dallas, TexasAges 18 years+ - NCT07836452RecruitingPhase 1
Study of a new drug for healthy people and those with Stargardt disease
This study tests a new drug called CITY-RBP4 in healthy volunteers and in people with Stargardt disease (STGD1), a genetic condition that causes vision loss. The goal is to see if the drug is safe and how it affects the body, which may help guide future treatments for Stargardt disease.
Melbourne, VictoriaAges 12–45 - NCT07785934RecruitingPhase 1
Testing a new weight management injection for drug interactions
This study tests a new injectable medication for weight management in people with overweight or obesity. It investigates how the drug interacts with other medications and checks its safety. Participation requires a 6-month commitment with regular study visits.
Hefei, AnhuiAges 18–45 - NCT07429240RecruitingPhase 1/Phase 2
Gene editing trial for Duchenne muscular dystrophy (ages 2-7)
This trial tests a new gene editing treatment called PBGENE-DMD for boys with Duchenne muscular dystrophy (DMD) whose genetic mutation falls within a specific range of the dystrophin gene (exons 45-55). The goal is to see if it is safe and can help improve muscle function.
Little Rock, ArkansasAges 2–7 - NCT06337942Recruiting
Bladder or kidney-bladder transplant from a deceased donor
This trial offers a first-in-human transplant of a bladder or a kidney combined with a bladder from a deceased donor. It is for people with severe bladder problems or bladder cancer who already need a new bladder or are on immune-suppressing medicines for a prior organ transplant.
Los Angeles, CaliforniaAges 18–70 - NCT07263386RecruitingPhase 2
Immunotherapy plus chemo for PD-L1-positive stomach cancer
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) after surgery helps prevent stomach cancer from returning. It’s for people whose tumors have a protein called PD-L1 and who had cancer in at least 7 lymph nodes.
Nanjing, JiangsuAges 18–75 - NCT07256301RecruitingPhase 1
Testing EA5 in adults with paroxysmal nocturnal hemoglobinuria (PNH)
This clinical trial tests an investigational drug called EA5 for people with PNH, a rare blood disease where red blood cells break down too quickly. It is for adults who either have never taken a complement inhibitor or stopped taking one recently, and who still have signs or symptoms of PNH.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06811870RecruitingPhase 1/Phase 2
Hyperbaric oxygen before surgery for breast cancer
This trial tests adding hyperbaric oxygen (breathing pure oxygen in a pressurized chamber) before standard chemotherapy for breast cancer. The goal is to see if it helps shrink the tumor more effectively before surgery.
Guangzhou, GuangdongAges 18–60 - NCT06072430RecruitingPhase 3
Testing a new fluid for septic shock with low blood pressure
This study tests an investigational fluid called VBI-S to see if it can help raise blood pressure in people with septic shock who are not responding to standard fluids. You may qualify if you have severe infection and low blood pressure that needs medication support.
Chandler, ArizonaAges 18 years+ - NCT07160725RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial is testing a new drug (BMS-986517) for people with advanced solid tumors, including certain lung, head and neck, and breast cancers. The goal is to see if the drug is safe and effective.
Irvine, CaliforniaAges 18 years+ - NCT07073547RecruitingPhase 1
Study of AZD0120 for multiple myeloma patients
This trial tests a new drug, AZD0120, in people with multiple myeloma. It aims to find the right dose and see how safe and effective it is. The study includes both newly diagnosed and early relapsed patients.
Phoenix, ArizonaAges 18 years+ - NCT03851523Recruiting
Tracking memory changes in people with early Alzheimer’s symptoms
This study follows people over time to better understand how memory and thinking complaints progress in early Alzheimer’s disease (from “subjective cognitive decline” to mild cognitive problems). It may help researchers understand who is likely to decline and how symptoms change, which could support future treatments.
Barcelona, CataloniaAges 45 years+ - NCT06938867RecruitingPhase 1/Phase 2
Study of SNIPR001 for stem cell transplant patients
This trial tests an oral treatment called SNIPR001 that targets a type of E. coli bacteria resistant to common antibiotics. It may help prevent infections during stem cell transplant recovery.
Duarte, CaliforniaAges 18 years+ - NCT06908434RecruitingPhase 1
GenSci128 for solid tumors with TP53 Y220C mutation
This trial tests a new drug, GenSci128, for people whose solid tumors have a specific TP53 Y220C mutation. The drug aims to reactivate the p53 protein to fight cancer. It is for patients who have exhausted standard treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06906562RecruitingPhase 2
Pemigatinib for advanced pancreatic cancer with FGFR changes
This trial tests a targeted pill, pemigatinib, for people with advanced pancreatic cancer that has a specific FGFR gene change. The study is done entirely through telemedicine, so you can participate from home if eligible.
Birmingham, AlabamaAges 18 years+ - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06725758RecruitingPhase 1/Phase 2
First-in-human study of ODM-212 for advanced solid tumors
This study tests an experimental drug called ODM-212 for people with advanced solid tumors that have not responded to standard treatments. It may be especially relevant if your tumor has changes in the Hippo pathway (certain genes like NF2 or YAP/TAZ).
Los Angeles, CaliforniaAges 18 years+ - NCT06641648RecruitingPhase 1
Donor NK cells with low-dose IL-2 for AML relapse after stem cell transplant
This trial tests a new treatment for patients whose acute myeloid leukemia (AML) has come back after a stem cell transplant. It uses immune cells from the original donor, combined with a low dose of a protein called IL-2, to try to fight the leukemia without causing severe side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06233942RecruitingPhase 1
Testing a new drug for advanced solid tumors
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06126588RecruitingPhase 2
Everolimus and Lutathera for refractory meningioma
This trial tests a combination of two drugs (everolimus and 177Lu-DOTATATE) for people with grade 2 or 3 meningioma that has grown despite prior treatments. It aims to see if this combination can slow or stop tumor growth.
Vandœuvre-lès-Nancy, Grand EstAges 18–80
Hear when a new Phase 2 Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for phase 2 study?
- Yes. Clin2 currently lists 1,327 recruiting phase 2 study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a phase 2 study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a phase 2 study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.